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Hyperekplexia is a rare neurological disorder characterized by neonatal hypertonia, exaggerated startle responses to
unexpected stimuli and a variable incidence of apnoea, intellectual disability and delays in speech acquisition. The
majority of motor defects are successfully treated by clonazepam. Hyperekplexia is caused by hereditary mutations
that disrupt the functioning of inhibitory glycinergic synapses in neuromotor pathways of the spinal cord and
brainstem. The human glycine receptor α1 and β subunits, which predominate at these synapses, are the major
targets of mutations. International genetic screening programs, that together have analysed several hundred
probands, have recently generated a clear picture of genotype-phenotype correlations and the prevalence of
different categories of hyperekplexia mutations. Focusing largely on this new information, this review seeks to
summarise the effects of mutations on glycine receptor structure and function and how these functional alterations
lead to hyperekplexia.
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Hyperekplexia (OMIM #149400), or human startle disease,
was first reported in 1958 by Kirstein and Silfverskiold [1].
They described a family in which four members suffered
sudden falls precipitated by ‘emotional’ stimuli including
surprise, fear or stress. In 1966, Suhren and colleagues re-
ported similar symptoms in a larger pedigree that were
shown to be inherited in an autosomal dominant manner
and were treatable by barbiturates [2]. We now know that
hyperekplexia is a rare neurological disorder characterized
by 1) episodic and generalized stiffness after birth which
gradually subsides during the first years of life, 2) an
increased likelihood of apnoea attacks, delayed speech ac-
quisition and/or intellectual disability, 3) excessive startle
reflexes to unexpected stimuli, particularly auditory or
tactile, that persist throughout life, and 4) a transient
generalized stiffness after startle reflexes that can result in
injurious falls [3-6]. The classic startle response is charac-
terized by forceful closure of eyes, rising of bent arms over
the head and flexion of the neck, trunk, elbows, hips and
knees (Figure 1). Consciousness is fully retained during* Correspondence: j.lynch@uq.edu.au
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article, unless otherwise stated.these episodes, thus distinguishing hyperekplexia from epi-
leptic seizures. Clonazepam, a benzodiazepine that posi-
tively modulates inhibitory synaptic gamma aminobutyric
acid (GABA) type-A receptor chloride channels, is a highly
effective treatment [3].
Shiang and colleagues were first to show that hyperek-
plexia is caused by hereditary mutations in the GLRA1
gene that encodes the α1 subunit of the inhibitory human
glycine receptor (hGlyR) chloride channel [7]. Although
the GLRA1 gene represents the major gene of effect [8,9],
hyperekplexia can also be caused by mutations in the
GLRB gene which encodes the hGlyR β subunit [10-15] or
in the SLC6A5 gene which encodes the presynaptic glycine
transporter type-2 [16-19]. Mutations have also been iden-
tified in the genes encoding the hGlyR synaptic clustering
proteins, gephyrin [20] and collybistin [21]. However, the
phenotypes resulting from the later mutations are more
complex than the classical phenotype described above.
The common feature of all these proteins is that they are
required for the normal functioning of inhibitory glyciner-
gic synapses. As a large proportion of hyperekplexia cases
have no genetic explanation [4], the analysis of other pro-
teins involved in the development or function of glyciner-
gic synapses could reveal further susceptibility genes. Attral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Schematic of a hyperekplexia patient illustrating the sequence of movements during a startle reflex. Numbers represent
elapsed time in ms. Reproduced with permission from Elsevier [2].
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is not well understood.
Inhibitory glycinergic synapses are located predomin-
antly in the spinal cord and brainstem [22-24] and dis-
ruptions to their function increase the general level of
excitability of motor neurons, thus accounting for neo-
natal hypertonia. Although patients seem to develop
compensatory mechanisms to cope with this chronically
enhanced excitability, they are not able to deal with the
increased inhibitory demand required to dampen strong,
unexpected excitatory commands [3].
Recently, thanks to large-scale systematic genetic
screening programs, several hundred hyperekplexia pro-
bands have been examined and the results have generated
a clear picture of the type and prevalence of mutations,
their inheritance modes and the mechanisms by which
they affect hGlyR structure and function [8,9,11,12,25].
The field may thus be considered to have reached a state
of maturity. The clinical presentation and genotype-
phenotype correlations in hyperekplexia have recently
been published [4,5,26]. The aim of this review is to sum-
marise the effects of mutations on hGlyR structure and
function and how these functional alterations lead to
hyperekplexia.
Molecular structure, stoichiometry and expression
of GlyRs
GlyRs belong to the Cys-loop family of pentameric ligand-
gated ion channel (pLGIC) receptors. The X-ray molecular
structures of several pLGIC receptors have been solved,
including two bacterial homologues crystallized in the
closed and open states, respectively [27-29], a nicotinic
acetylcholine receptor (nAChR) from T. marmorata [30]
and a glutamate-gated chloride channel receptor from C.
elegans [31]. As this later receptor exhibits ~34% sequencehomology with the α1 hGlyR subunit, it provides an excel-
lent molecular structural template. As shown in Figure 2A,
B GlyRs consist of five subunits arranged symmetrically in
a ring around a central ion-conducting pore. Each subunit
contains an extracellular domain (ECD), comprised mainly
of a twisted β-sheet sandwich, harbouring the ligand bind-
ing site, and a transmembrane domain (TMD) comprising
four α-helices, termed TM1 – TM4, with the five TM2 do-
mains lining the axial channel pore. Both the extracellular
β-sheets and transmembrane α-helices are connected by
flexible loops. Glycine binds at the extracellular subunit
interface and maximum gating efficacy is reached when
three of the five binding sites are occupied [32]. Upon gly-
cine binding, each ECD rotates relative to its TMD, ultim-
ately inducing an outward tilt of the top of the TM2
domains which then opens the pore [33-35].
In humans, four α subunits (α1 – α4) and a single β sub-
unit have been described. The human α4 subunit is consid-
ered a pseudogene on the grounds that it incorporates a
premature stop codon upstream of the final TM4 domain
[36]. hGlyRs exist either as α homomers or as αβ hetero-
mers in a stoichiometry of 2α:3β [37,38] or 3α:2β [39]. As
the β subunit mediates hGlyR attachment to the sub-
synaptic clustering protein, gephyrin [40], it is presumed
that only heteromeric αβ hGlyRs are present in synapses.
Embryonic rats express predominantly α2 subunits, with
the onset of β subunit expression coinciding with the first
appearance of glycinergic synapses around the time of birth
[41]. By three weeks postnatal in the rat spinal cord, most
α2 subunits have been replaced by α1 subunits. In the adult
spinal cord, α1 and β subunits are expressed in glycinergic
synapses in motor reflex arcs, whereas α1, α3 and β sub-
units are all expressed in inhibitory synapses in pain sen-
sory neurons in the superficial laminae of the dorsal horn
[42]. In the cerebral cortex and hippocampus, GlyRs are
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Figure 2 pLGIC structure and the locations of hGlyR hyperekplexia mutations. The top panel shows the pentameric structure of the C.
elegans α glutamate-gated chloride channel receptor (PDB 3RIF [31]) viewed from within the membrane (A) and from the presynaptic terminal
(B). One subunit is coloured light grey. Panels C-F show a single pLGIC subunit with the locations of dominant and recessive mutations in the α1
and β hGlyR subunits coloured in green (missense), red (nonsense) or black (deletions). TM2 is coloured dark grey.
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mers or α2β heteromers [43-46]. This expression pattern
implies that α1 and β subunits should be targets of hyper-
ekplexia mutations whereas α2 and α3 subunits should not.
Hyperekplexia mutations in the hGlyR α1 subunit
Relationship between mutation type and inheritance mode
Most α1 hGlyR hyperekplexia mutations are either mis-
sense mutations whereby a single nucleotide changeresults in a codon change for a different amino acid, or
nonsense mutations whereby a single nucleotide change
leads to a premature stop codon (Table 1). Large dele-
tions are also found, especially deletions of exons 1 – 7 in
families of Turkish origin, suggesting that this is a
population-specific risk-allele [9]. Hyperekplexia mutations
can be inherited in both autosomal dominant or recessive
modes with the majority of mutations being recessive
(Table 1). Recessive mutations can be homozygous recessive,
Table 1 Hyperekplexia mutations in GLRA1
Mutation Mutation type Inheritance hGlyR position Notes Reference
ΔEx1-7 deletion recessive n.a. [50]
ΔEx4-7 deletion recessive n.a. compound heterozygous with R65L [9]
R65L missense recessive ECD compound heterozygous with ΔEx4-7 [9]
R65W missense recessive ECD compound heterozygous with P230S [9]
W68C missense recessive ECD compound heterozygous with R316X [51]
R72fsX47 deletion recessive ECD [52]
R72H missense recessive ECD [53]
R72C missense recessive ECD [8]
E103K missense recessive ECD compound heterozygous with L184fsX21 [9]
Y128C missense dominant ECD [9]
K132fsX15 deletion recessive ECD [54]
C138S missense recessive ECD compound heterozygous with D148fsX16 [55]
M147V missense recessive ECD [52]
D148fsX16 deletion recessive ECD compound heterozygous with C138S [55]
D165G missense recessive ECD [9]
W170S missense recessive ECD [56]
L184fsX21 deletion recessive ECD compound heterozygous with E103K [9]
Y197X nonsense recessive ECD compound heterozygous with Y202X [9]
Y202X nonsense recessive ECD compound heterozygous with Y197X [52]
R218Q missense de novo ECD compound heterozygous with S296X [49]
R218W missense recessive ECD [8]
Q226E missense dominant TM1 [8]
Y228C missense recessive TM1 [57]
P230S missense recessive TM1 compound heterozygous with R65W [8]
S231R missense recessive TM1 [58]
S231N missense recessive TM1 compound heterozygous with S296X [9]
W239C missense dominant TM1 [59]
I244N missense recessive TM1 [47]
P250T missense dominant TM1-TM2 loop [60]
R252H missense recessive TM2 compound heterozygous with R392H [48]
R252C missense recessive TM2 [9]
G254D missense recessive TM2 [9]
V260M missense dominant TM2 [49]
T265I missense dominant TM2 [9]
Q266H missense dominant TM2 [61]
S267N missense dominant TM2 [62]
S270T missense recessive TM2 [63]
R271L missense dominant TM2 [7]
R271Q missense dominant TM2 [7]
R271P missense dominant TM2 [64]
R271X nonsense dominant TM2 [13]
K276E missense dominant TM2-TM3 loop [65]
K276Q missense de novo TM2-TM3 loop [66]
Y279C missense dominant TM2-TM3 loop [67]
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Table 1 Hyperekplexia mutations in GLRA1 (Continued)
Y279X nonsense recessive TM2-TM3 loop [59]
Y279S missense dominant TM2-TM3 loop [68]
V280M missense dominant TM2-TM3 loop [8]
L291P missense recessive TM3 compound heterozygous with D388A [8]
S296X nonsense recessive TM3 compound heterozygous with S231N and R218Q [69]
R316X nonsense recessive TM3-TM4 loop compound heterozygous with W68C [51]
G342S missense recessive TM3-TM4 loop [70]
E375X nonsense recessive TM3-TM4 loop [8]
D388A missense recessive TM3-TM4 loop compound heterozygous with L291P [8]
R392H missense recessive TM4 compound heterozygous with R252H [48]
R414H missense dominant TM4 [8]
ECD extracellular binding domain, TM transmembrane.
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as first described in 1999 [48]. Mutations can also be de
novo meaning that neither parent possesses the mutation
[49]. To date, there is no evidence for a correlation be-
tween clinical traits and inheritance mode of GLRA1 mu-
tations [4].
GLRA1 nonsense and deletion/frameshift mutations,
which lead to a loss of protein expression at the cell sur-
face, are invariably autosomal recessive (Table 1). The
reason for this is that the unaffected allele can generate
sufficient quantities of protein to support normal glyci-
nergic neurotransmission. In contrast, autosomal domin-
ant mutations are missense mutations and invariably
express strongly in cell surface-expressed hGlyRs, but di-
minish GlyR current-carrying capacity via spontaneous
channel activity or via reductions in glycine sensitivity,
zinc sensitivity, open probability and/or single channel
conductance. Due to the efficient expression of these
mutated subunits, their deleterious effects cannot be res-
cued by the unaffected allele. Recessive mutations are
scattered throughout the α1 hGlyR subunit while dom-
inant mutations are clustered in and around the pore-
lining TM2 domain (Figure 2C, D).
Here, we describe the effects of those mutations
(mainly autosomal dominant) that provide useful in-
sights into the structure and function of hGlyRs and/or
the pathophysiological mechanisms of hyperekplexia.
Spontaneous activation
So far, four GLRA1 mutations resulting in spontaneous
channel activity have been identified: Y128C [9], Q226E,
V280M and R414H [8]. All four mutations are auto-
somal dominant and the mutated subunits express
strongly. Some possible mechanisms by which spontan-
eous hGlyR activation may give rise to hyperekplexia are
considered below.
Q226E, located at the top of the TM1 domain (Figure 3A,
B), also produces modest reductions in single channelconductance and cell surface expression efficiency that
may contribute to the hyperekplexia phenotype [8]. Recent
functional evidence suggests that Q226E induces receptor
activation via an enhanced electrostatic attraction to R271
located at the top of the TM2 domain in the neighbouring
subunit [25]. This attraction would tilt the top of the TM2
domain away from the pore axis, towards the TM1 do-
main, to constitutively open the channel. As detailed
below, R271 is also an important hyperekplexia locus.
V280M, in the TM2-TM3 loop, exhibits a dramatically
enhanced glycine sensitivity and spontaneous channel
activity suggesting a drastic destabilization of the closed
channel state [8]. We propose that the increased side
chain volume of V280M exerts a steric repulsion against
I225 at the top of the TM1 domain in the neighbouring
subunit [25]. This would tilt the top of the TM3 domain
radially outwards against the stationary TM1 domain
and thus provide space for the TM2 domain to relax
away from the pore axis to create an open channel.
Y128C is located in the inner β-sheet of the ECD. The
mechanism by which it induces spontaneous activity is
not yet resolved, but given its distance from the TMD, it
seems likely that it causes non-specific structural alter-
ations [9].
R414H, in the TM4 domain, results in a very low rate
of spontaneous activity and has weak, if any, effects on
glycine sensitivity, single channel conductance and ex-
pression efficiency [8]. It is thus unclear how this muta-
tion causes hyperekplexia. As R414H has recently been
identified as a rare single nucleotide polymorphism, it
may not actually be responsible for hyperekplexia in the
affected individual.
The high level of spontaneous activity in the Y128C,
Q226E and V280M mutant hGlyRs directly contributes
to the observed reduction in the glycine-induced current
amplitude [8,9]. The tonic chloride influx may also shift
the chloride equilibrium potential to more positive
values leading to a further reduction in the inhibitory
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Figure 3 Proposed mechanism by which Q226E induces spontaneous activation. The TM1 and TM2 helices are coloured green and red,
respectively, and are located in adjacent subunits. A. In the wild type (WT) α1 hGlyR, glycine induces activation by tilting the top of TM2 away
from the pore axis towards TM1, where the open state is weakly stabilized by an H-bond between Q226 and R271. Hyperekplexia mutations at
R271 are likely to disrupt this bond, thus destabilising the open state. B. In the Q226E mutant α1 hGlyR, a stable open state in the absence of
glycine is induced via the formation of a strong electrostatic bond between Q226E and R271.
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chronic depolarization that could lead to an increased
action potential firing rate. In addition to directly acti-
vating neurons, tonic hGlyR activation could result in
enhanced sodium and calcium influx rates. The effects
of the mutations could thus be similar to those of
nAChR slow-channel myasthenia mutations that result
in ‘cationic overload’ of the postsynaptic region which
destroys synaptic specializations and intracellular organ-
elles [71]. As discussed below, a hyperekplexia mutation
(L285R) in the hGlyR β subunit also causes spontaneous
channel activity.
Impaired channel gating
R271Q and R271L, at the extracellular end of the TM2
domain, are the most frequently occurring and the most
studied hyperekplexia mutations. They are both inher-
ited in an autosomal dominant manner [7,47,65,67,72].
A rare autosomal dominant mutation at this site, R271P,
is yet to be functionally characterized [64]. R271Q and
R271L do not impair cell surface expression but dramat-
ically reduce both the glycine sensitivity and the single
channel conductance [73-77]. The decrease in single
channel conductance most likely results from the elimin-
ation of the positive charge on R271. This would diminishthe ability of the pore to concentrate chloride ions in its
external vestibule, which would in turn reduce the chlor-
ide influx rate [25,78]. Unfortunately, however, the effects
of R271 mutations on glycine sensitivity do not have such
a simple molecular explanation.
The TM2-TM3 loop located adjacent to R271 is an
important structural element involved in transmitting
glycine binding signals from the binding site to the acti-
vation gate [33-35]. Given that this is achieved via a
highly organized network of energetic interactions be-
tween residues in the TM2-TM3 loop and the ECD, any
alteration to loop structure would be expected to impair
the efficient gating of the receptor, leading to reductions
in glycine sensitivity and maximum open probability
[79]. Evidence to date suggests that all hyperekplexia
missense mutations in this loop, including R271Q/L/P,
K276E/Q and Y279C/S, impair hGlyR function via
a similar mechanism [74,75,79-81]. As illustrated in
Figure 3, one specific effect of the R271 mutations is to
disrupt a hydrogen bond with Q226 that is required to
stabilise the open state [25]. Without this hydrogen
bond, the open state would be destabilized, thereby re-
ducing glycine sensitivity.
These and other mutations that impair channel gating
cause hyperekplexia by reducing the rate of chloride
Bode and Lynch Molecular Brain 2014, 7:2 Page 7 of 12
http://www.molecularbrain.com/content/7/1/2influx through synaptic hGlyRs. Depending on the muta-
tion, this may be achieved via a combination of a re-
duced maximum channel open probability, a reduced
single channel conductance and/or a reduced the glycine
sensitivity which would diminish the likelihood of the
channels being effectively activated by synaptic glycine
concentrations. The consequent reduction in glycinergic
current magnitudes would disinhibit motor neurons
thereby leading to enhanced firing activity and more po-
tent muscle contractions. As noted above, hyperekplexia
patients develop compensatory mechanisms to cope with
the level of excitatory activity required for normal motor
control [3]. One compensatory mechanism, identified in
mouse models of hyperekplexia, is an enhancement of
inhibitory GABAergic neutrotransmission [82], which
may explain why clonazepam is an effective treatment.
However, during startle episodes, the weakened inhibi-
tory system is unable to dampen the excessive level of
excitatory activity in motor neurons and the classic star-
tle response results.
Although hyperekplexia patients with R271Q/L muta-
tions are effectively treated with clonazepam [3,4,6],
novel alternate therapeutic strategies are emerging. In
one recent study, hGlyR function was restored by shift-
ing the R271Q/L residue out of the allosteric signalling
pathway via the mutation of surrounding residues [83].
This result raises the possibility of either designing or
re-purposing drugs that bind in the alcohol/anaesthetic
site near to R271 to achieve the same outcome [84]. In
addition, the anaesthetic and GlyR positive allosteric
modulator, propofol, preferentially enhances the potency
of glycine in R271Q/L relative to α1 wild type hGlyRs
[85,86], and indeed, propofol successfully normalized
hyperekplexia symptoms in a mouse carrying the R271Q
mutation [86]. As propofol binds in the deep cleft near
R271 [87], it offers a starting point for identifying novel,
more specific hyperekplexia treatments. Although the
development of new drugs to treat specific hyperekplexia
genotypes is unlikely to be economically viable, the re-
purposing of existing clinically-approved drugs may be a
realistic option.
The autosomal dominant mutation Q266H [61] in the
TM2 domain reduces glycine sensitivity and single chan-
nel open times indicating that it also disrupts receptor
gating efficacy [88]. Autosomal dominant hyperekplexia
mutations to other pore-lining residues, V260M, T265I
and S267N, similarly disrupt glycine efficacy [9,62,89].
Interestingly, the S267N mutation also abolishes hGlyR
ethanol sensitivity [62], although the sensitivity of the
patient to alcohol was not reported.
The autosomal dominant mutation R218Q in the ECD
produces a dramatically reduced sensitivity to glycine,
which is probably the primary reason for its hyperek-
plexia phenotype [49,89]. Low concentrations of thecompetitive antagonist strychnine were similarly antago-
nized in wild type and R218Q-containing receptors sug-
gesting that residue R218 plays an important role in
channel gating, with only minor effects on glycine bind-
ing [89]. Recently, it was shown that the R218Q muta-
tion disrupts a salt bridge between R218 and N148 that
is crucial for efficient gating [90].
Increased desensitization rate
The autosomal dominant P250T mutation in the TM1-
TM2 loop reduces glycine-activated current amplitudes
and induces fast desensitization with a time constant
near 120 ms [60,91]. The reduced whole-cell current
amplitude can be explained by a dramatic reduction in
single channel conductance from around 80 to 1.3 pS,
which no doubt accounts for much of the hyperekplexia
phenotype [60]. In contrast, glycine sensitivity, affinity
for strychnine and cell surface expression were similar
to wild type receptors. Mutagenesis screening of neigh-
bouring residues in the TM1-TM2 loop demonstrated
that P250 is by far the most critical residue with respect
to desensitization and glycine sensitivity [91]. Molecular
dynamics simulations revealed an increased flexibility in
P250T mutant hGlyRs which would destabilize the open
state and explain the observed rapid desensitization [92].
The same publication also suggested that receptor activa-
tion and desensitization are structurally distinct processes
as recently supported by a voltage-clamp fluorometry
study [93]. As glycinergic synaptic currents exhibit decay
time constants of 5 – 10 ms, it is unclear whether the en-
hanced desensitization rate induced by P250T is sufficient
to limit chloride flux through the mutant channels and
thereby contribute to the hyperekplexia phenotype.
The P230S hyperekplexia mutation in the TM1 domain
also induces fast desensitization with a time constant near
1 s [8]. Additionally, this mutation reduces glycine sensi-
tivity and maximal glycine-induced current amplitudes in-
dependent of β subunit co-expression. Genetic analysis of
the patient with the P230S mutation suggested possible
heterozygosity with R65W, although parental DNA was
not available to confirm this. However, given the severity
of the functional deficits resulting from the P230S muta-
tion, we speculate it was most likely autosomal dominant.
The R65W mutation eliminates cell surface expression
and results in a recessive form of hyperekplexia [9].
Reduced cell surface expression
Many hyperekplexia mutations reduce cell surface expres-
sion, thereby reducing the maximal glycine-induced
current amplitude. For the autosomal recessive mutations,
S231R and I244N, both located in the TM1 domain,
R252H in the TM2 domain and R392H in the TM4 do-
main, it was shown that treatment with the proteasome
blocker lactacystin significantly increased the accumulation
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gesting that the mutated subunits were recognized by the
endoplasmatic reticulum control system and then de-
graded via the proteasome pathway [94]. Thus, the loss of
glycinergic inhibition associated with many recessive
hyperekplexia phenotypes may be due to the sequestration
of mutated subunits within the endoplasmatic reticulum
quality control system.
hGlyRs incorporating premature stop codons usually
do not form functional receptors at the cell surface
[9,69,95]. However, it has recently been shown that the
autosomal recessive truncation mutation, E375X, which
truncates the α1 hGlyR upstream of the TM4 domain,
can be incorporated into functional receptors together
with α1 wild type subunits [8]. hGlyRs containing the
truncated subunit exhibited low cell surface expression
and reduced glycine sensitivity. As this truncation occurs
upstream of the naturally occurring premature stop
codon in the human GLRA4 gene, it suggests that a re-
view of the presumed pseudogene status of GLRA4
[24,36] and of other similarly classified pLGIC genes
may be warranted.
Loss of zinc potentiation
Low concentrations of zinc (0.01 - 10 μM) have long
been known to potentiate hGlyRs [96]. As zinc is con-
centrated in presynaptic terminals in the spinal cord and
is released upon neuronal stimulation, its potentiating
effect on glycinergic currents is likely to be physiologicallyTable 2 Hyperekplexia mutations in GLRB
Mutation Mutation type Inheritance GlyR
ΔEx1-8 deletion recessive
Splice site mutation In4 (c.298-1G > A) missense recessive
ΔEx5 deletion recessive
ΔEx5 and S176RfsX6 deletion recessive
E24X nonsense recessive
R50X nonsense recessive
P169L missense recessive
M177R missense recessive
R190X nonsense recessive
F19IfsX3 deletion recessive
Q216fsX222 deletion recessive
G229D missense recessive
△S262 deletion recessive
L285R missense de novo
W310C missense recessive TM2-
S321F missense recessive
R450X nonsense recessive TM3-
Y470C missense dominant
ECD extracellular binding domain, TM transmembrane.relevant. Indeed, hyperekplexia symptoms were present in
a genetically-modified mouse harbouring a mutant (D80A)
α1 subunit that abolished zinc potentiation [97]. Recently,
the GLRA1 V170S mutation was shown to produce an
autosomal dominant form of hyperekplexia [56]. When
these mutant receptors were recombinantly expressed in a
mammalian cell line, V170S was found to have no effect
on glycine sensitivity although it completely eliminated
zinc potentiation [98]. This result implies that hyperek-
plexia can result from a reduction in glycinergic current
magnitude due to the elimination of zinc potentiation.
Hyperekplexia mutations in the hGlyR β subunit
The GLRB gene has only recently been identified as a
major gene of effect in hyperekplexia [10-12] although
the first GLRB hyperekplexia mutation was identified in
2002 [15]. To date, one autosomal dominant mutation,
Y470C, is known [11], although the de novo L285R sub-
stitution is also likely autosomal dominant given the na-
ture of its effect on receptor function (see below) and
the fact that it was identified in a heterozygous proband
[12]. The remaining mutations are autosomal recessive
as either homozygous recessive or as compound hetero-
zygous (Table 2). Around half of these mutations result
in the excision of large amounts of β subunit protein
which would most certainly eliminate functional expres-
sion. Most of the remaining mutations (P169L, M177R,
G229D, △S262, W310C, R450X, Y470C) either reduce
cell surface expression of functional heteromeric hGlyRsposition Notes Reference
n.a. [11]
n.a. compound heterozygous with S321F [13]
n.a. compound heterozygous with G229D [15]
n.a. [11]
ECD [11]
ECD compound heterozygous with Q216fsX222 [14]
ECD [11]
ECD [10]
ECD compound heterozygous with △S262 [11]
ECD [11]
ECD compound heterozygous with E24X [14]
ECD compound heterozygous with ΔEx5 [15]
TM1 compound heterozygous with R190X [11]
TM2 [12]
TM3 loop [12]
TM3 compound heterozygous with In4 (c.298-1G > A) [13]
TM4 loop [11]
TM4 [11]
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[11,12,15], both of which are typical effects of recessive
mutations. Although molecular modelling has provided
insight into possible structural defects caused by these
mutations [11,12], experimental support for most of the
model predictions is lacking to date.
The de novo mutation, L285R, provides an exception
to the above pattern of effect on the grounds that it pro-
duces spontaneous channel activity when co-expressed
with α1 wild type hGlyR subunits [11,12], and because
structural basis of its defect can be inferred with confi-
dence. L285 is located at the 9′ position in the middle of
the pore-lining TM2 domain [30]. It has long been rec-
ognized that 9′ leucines are very highly conserved
among pLGIC receptors. These hydrophobic leucines
protrude into the pore and their presence on each of the
five subunits enables them to form a pentameric radially
symmetrical arrangement of hydrophobic bonds that
holds the channel closed. As many functional studies
have demonstrated [99-102], substitution of one or more
of these leucines with polar or charged residues disrupts
some of the bonds, leading to a collapse of symmetry
and the conversion of all TM2 domains to the open pore
conformation. Thus, one mutated subunit per receptor
would be sufficient to cause a significant, potentially
damaging, chloride leak current.
Unlike GLRA1 mutations, GLRB mutations are
strongly associated with delays in gross motor develop-
ment and speech acquisition in humans [4]. This fact re-
sembles the situation in zebrafish, where morpholino
knockdown of the zebrafish orthologues of GLRA1 and
GLRB results in distinct startle phenotypes [103]. The
differential effect in mammals may be explained by the
fact that β subunits are expressed at a much earlier de-
velopmental stage than α1 subunits, where they are in-
volved in the formation of the first glycinergic synapses
together with α2 subunits [23,104].
Conclusions
GLRA1 and GLRB hyperekplexia mutations can be
grouped into three main categories. The first includes
those dominant mutations located in and around the
TM2 domain that do not impair cell surface expression
but disrupt hGlyR function by either inducing spontan-
eous channel activity or by reducing glycine sensitivity,
chloride conductance and/or open probability. The sec-
ond category includes those recessive missense muta-
tions located throughout the receptor that result in a
deficiency in cell surface targeting of hGlyRs. The final
category includes recessive nonsense and deletion/
frameshift mutations, the so called null genotypes, which
preclude the formation of full length functional penta-
mers. The analysis of the molecular mechanisms of these
mutations has provided unexpected insights into thestructure and function of GlyRs and also into glycinergic
signaling mechanisms in health and disease. By describ-
ing some of these molecular mechanisms, we hope that
we have been able to provide explanations for the phe-
notypes of many gene-positive patients.
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